Insulet stock falls after weaker 2026 guidance

Insulet (US45784P1012) stock is under pressure after the company cut its 2026 revenue growth forecast to 20 percent to 22 percent from 21 percent to 23 percent and guided third-quarter revenue to USD 833.4 million, below analyst expectations of USD 847.3 million, according to a same-day report on September 5, 2026.

Guidance now matters most

The second quarter still showed strong top-line momentum. Insulet reported revenue of USD 801.7 million, up 23.5 percent year on year, and adjusted EPS of USD 1.66, which topped expectations by 14.3 percent, the report said.

That split is the key message for investors: the latest quarter was solid, but the full-year view is less ambitious than before. The stock reaction reflects that tension between current execution and a softer outlook.

Omnipod sales drive the debate

Insulet's Omnipod insulin delivery platform remains the core business, and the latest update ties the guidance cut to slower US sales. The company still expects 2026 revenue growth of 20 percent to 22 percent, a range that frames the rest of the year.

The numbers also show how narrow the market focus has become. Revenue of USD 801.7 million in the second quarter and Q3 guidance of USD 833.4 million are now the figures most likely to shape sentiment.

Omnipod stays central

Omnipod is the product investors are watching most closely because it drives both revenue growth and the debate over US demand. The latest update suggests the platform is still expanding, but at a slower pace than the market had modeled.

Stock and market view

The share price line should be read against the guidance reset and the Q2 beat on revenue and adjusted EPS. For investors, the next debate is less about the second quarter and more about whether the 2026 range can be stabilized.